Share on StockTwits

Stock analysts at Roth Capital upped their price objective on shares of Durata Therapeutics (NASDAQ:DRTX) from $24.00 to $28.00 in a note issued to investors on Tuesday. Roth Capital’s target price would suggest a potential upside of 59.82% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Gabelli initiated coverage on shares of Durata Therapeutics in a research note on Friday, June 20th. They set a “hold” rating on the stock. Separately, analysts at JMP Securities reiterated an “outperform” rating on shares of Durata Therapeutics in a research note on Thursday, June 19th. They now have a $22.00 price target on the stock, up previously from $19.00. Finally, analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $19.00 to $23.00 in a research note on Tuesday, May 27th. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Durata Therapeutics presently has an average rating of “Buy” and an average target price of $20.38.

Durata Therapeutics (NASDAQ:DRTX) traded up 2.88% on Tuesday, hitting $17.52. 320,810 shares of the company’s stock traded hands. Durata Therapeutics has a 1-year low of $7.11 and a 1-year high of $17.74. The stock’s 50-day moving average is $16.17 and its 200-day moving average is $13.91. The company’s market cap is $466.8 million.

Durata Therapeutics (NASDAQ:DRTX) last announced its earnings results on Thursday, May 8th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.02. On average, analysts predict that Durata Therapeutics will post $-2.44 earnings per share for the current fiscal year.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.